Mentice AB (publ) (MNTC) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. My name is Richard Engberg, and I'm an equity research analyst here at Carnegie Investment Bank. With me, I am Frans Fenker, CEO of Mentis, and Ulrika Dross, CFO of Mentis. We're going to present the first quarter. Frans and Ulrika, welcome. Thank you, Richard. Thanks for having us. So the scene is yours. Very good. Thank you, Richard, for us being here. What we have today is the quarterly results for the first quarter, which we are happy to present to you and all of you. So what I have is four topics for today. First of all, the highlights and also the interview, basically overview presented by me, the financial results by Ulrika Drots, concluding remarks by me, and then we go towards questions and answers. Overall, if we look at the quarterly summary, what we see is that we had solid revenue growth year over year, where the net sales was up by close to 20%. What we saw is that the EBITDA was negatively impacted by one-offs. That was due to restructuring, but also due to currency effects. The revenue came from all three regions, so we were positive from all three regions, specifically North America from an absolute standpoint. From a percentage point also, we saw significant growth by APAC, although from a lower base. What we are doing is currently addressing the weak developments in the healthcare systems market by addressing also our value proposition. So really the growth also from an order intake came from the medical device industry. Overall order intake increased by 15% year over year and it signaled also a strong interest for our Mentus products going forward. Now, if you then look at the business development activities. So, first of all, there are activities, and we have put activities in place in order to streamline the organization ...